FDA Warns of Adverse Events Linked to Unapproved Compounded Versions of Ozempic and Wegovy

FDA Warns of Adverse Events Linked to Unapproved Compounded Versions of Ozempic and Wegovy

The U.S. Food and Drug Administration has warned consumers and health care providers about compounded versions of semaglutide, the active ingredient in the approved drugs Ozempic, Wegovy and Rybelsus. The agency reported receiving adverse event reports tied to these products, including hospitalization, gastroenteritis and medication errors. [1] In its safety communication, the FDA stated that some compounded semaglutide contains salt forms—semaglutide sodium and semaglutide acetate—that have not been shown to be safe or effective. [1]

The update addresses increased demand and related shortages that have driven compounding activity. Primary FDA documents clarify the regulatory line between approved medications that completed full pre-market review and compounded versions produced outside that process. [2]

What this means

The FDA’s observations link compounded semaglutide to adverse events that include severe gastrointestinal distress and dosing mistakes. The data suggest quality differences between FDA-approved products, which underwent rigorous evaluation, and compounded versions that bypass standard approval pathways. Only Ozempic, Wegovy and Rybelsus have been reviewed by the agency for safety and efficacy. [2]

Adverse Events Reported

The FDA has received adverse event reports including hospitalization, gastroenteritis and medication errors linked to compounded semaglutide. [1] These reports describe cases of severe gastrointestinal symptoms and incorrect dosing with injectable compounded formulations.

Salt Forms Used in Compounding

Compounded semaglutide may contain unapproved salt forms. Semaglutide sodium and semaglutide acetate have not been shown to be safe or effective. [1] The agency’s communication explicitly identifies these forms as distinct from the base compound evaluated in approved products.

Regulatory Framework for Compounding

Compounding of semaglutide is permitted only when there is a documented shortage of the FDA-approved drug and under section 503A or 503B conditions. [3] FDA policy documents describe these limits as a way to manage supply gaps while applying federal manufacturing standards.

Approved Products

Only FDA-approved semaglutide products—Ozempic, Wegovy and Rybelsus—have been evaluated for safety and efficacy. [2] The agency’s records show these three medicines completed the full pre-market review process that compounded drugs do not undergo.

Scope of the Safety Communication

The FDA is warning consumers and health care providers against the use of compounded semaglutide products because they may contain salt forms (semaglutide sodium or semaglutide acetate) that have not been shown to be safe and effective, or may be produced using bulk substances that do not meet federal safety standards. [1] Adverse event reports include hospitalization, severe gastrointestinal distress and dosing errors from compounded injectable semaglutide. The agency reiterates that only FDA-approved products have been evaluated for safety and efficacy. [2]

Limitations

Voluntary adverse-event reporting may under-represent total incidents. The communication does not include independent laboratory analysis of every compounded product on the market or provide a comprehensive list of compliant compounding pharmacies. Long-term safety data specific to compounded formulations are unavailable.